Amniotic Fluid Embolism: Anaphylactic Reactions With Idiosyncratic Adverse Response

Obstetrical and Gynecological Survey

Volumn 70, Issue 8, 2015, Pages 511-517

  Kobayashi, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FETAL ANTIGEN; IMMUNOGLOBULIN E;

ADVERSE DRUG REACTION; AMNION FLUID; AMNION FLUID EMBOLISM; ANAPHYLAXIS; CARDIOPULMONARY ARREST; CELL ACTIVATION; CHECKLIST; CLINICAL PRACTICE; COMPLEMENT ACTIVATION; FEMALE; FETUS OUTCOME; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IDIOSYNCRATIC ADVERSE RESPONSE; INTENSIVE CARE UNIT; MAST CELL; PERINATAL MORTALITY; PLACENTA CIRCULATION; POSTPARTUM HEMORRHAGE; PREGNANT WOMAN; PUERPERIUM; RESUSCITATION; REVIEW; SUDDEN CARDIOPULMONARY COLLAPSE; ADULT; COMPLICATION; HISTOCOMPATIBILITY; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; PREGNANCY;

ADULT; AMNIOTIC FLUID; ANAPHYLAXIS; EMBOLISM, AMNIOTIC FLUID; FEMALE; HISTOCOMPATIBILITY, MATERNAL-FETAL; HUMANS; POSTPARTUM PERIOD; PREGNANCY;

EID: 84940536853     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0000000000000197     Document Type: Review

References (41)

1. Clark SL, Hankins GD, Dudley DA, et al. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol. 1995;172: 1158-1167.
2. Thongrong C, Kasemsiri P, Hofmann JP, et al. Amniotic fluid embolism. Int J Crit Illn Inj Sci. 2013;3:51-57.
3. Knight M, Berg C, Brocklehurst P, et al. Amniotic fluid embolism incidence, risk factors and outcomes: a reviewand recommendations. BMC Pregnancy Childbirth. 2012;12:7.
4. Kanayama N, Inori J, Ishibashi-Ueda H, et al. Maternal death analysis from the Japanese autopsy registry for recent 16 years: significance of amniotic fluid embolism. J Obstet Gynaecol Res. 2011;37:58-63.
5. Rath WH, Hoferr S, Sinicina I. Amniotic fluid embolism: an interdisciplinary challenge: epidemiology, diagnosis and treatment. Dtsch Arztebl Int. 2014;111:126-132.
6. Ito F, Akasaka J, Koike N, et al. Incidence, diagnosis and pathophysiology of amniotic fluid embolism. J Obstet Gynaecol. 2014;27:1-5.
7. Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol. 2009;201:445. e1-13.
8. Tuffnell DJ. United kingdom amniotic fluid embolism register. BJOG. 2005;112:1625-1629.
9. Kanayama N, Yamazaki T, Naruse H, et al. Determining zinc coproporphyrin in maternal plasma-a new method for diagnosing amniotic fluid embolism. Clin Chem. 1992;38:526-529.
10. Kobayashi H, Ohi H, Terao T. A simple, noninvasive, sensitive method for diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GalNAc. Am J Obstet Gynecol. 1993;168:848-853.
11. Oi H, Naruse K, Noguchi T, et al. Fatal factors of clinical manifestations and laboratory testing in patients with amniotic fluid embolism. Gynecol Obstet Invest. 2010;70:138-144.
12. Legrand M, Rossignol M, Dreux S, et al. Diagnostic accuracy of insulin-like growth factor binding protein-1 for amniotic fluid embolism. Crit Care Med. 2012;40:2059-2063.
13. Naruse K, Noguchi T, Yoshida S, et al. Identification of interleukin-6 (IL-6) and squamous cell carcinoma (SCC) as amniotic fluid-specific markers. Open J Obstet Gynecol. 2012;2:147-150.
14. Davies S. Amniotic fluid embolus: a review of the literature. Can J Anaesth. 2001;48:88-98.
15. Clark SL. Amniotic fluid embolism. Obstet Gynecol. 2014;123: 337-348.
16. Tsunemi T, Oi H, Sado T, et al. An overview of amniotic fluid embolism: past, present and future directions. Open Womens Health J. 2012;6:24-29.
17. Kobayashi H. The entry of fetal and amniotic fluid components into the uterine vessel circulation leads to sterile inflammatory processes during parturition. Front Immunol. 2012;3:321.
18. Busardó FP, Gulino M, Luca DI, et al. Not only a clinical nightmare: amniotic fluid embolism in court. Curr Pharm Biotechnol. 2014;14:1195-1200.
19. Aurangzeb I, George L, Raoof S. Amniotic fluid embolism. Crit Care Clin. 2004;20:643-650.
20. Mulder JI. Amniotic fluid embolism: an overview and case report. Am J Obstet Gynecol. 1985;152:430-435.
21. Ray BK, Vallejo MC, Creinin MD, et al. Amniotic fluid embolism with second trimester pregnancy termination: a case report. Can J Anaesth. 2004;51:139-144.
22. Greenberger PA, Ditto AM. Chapter 24: anaphylaxis. Allergy Asthma Proc. 2012;33(suppl 1):S80-S83.
23. Benson MD. Nonfatal amniotic fluid embolism. Three possible cases and a new clinical definition. Arch Fam Med. 1993;2:989-994.
24. Oza NB, Ryan JW, Ryan US, et al. Pulmonary anaphylaxis and the kallikrein-kinin system. Adv Exp Med Biol. 1979;120A:473-486.
25. Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci. 2005;99:6-38.
26. Bossi F, Bulla R, Tedesco F. Endothelial cells are a target of both complement and kinin system. Int Immunopharmacology. 2008; 8:143-147.
27. Ghebrehiwet B, CebadaMora C, Tantral L, et al. gC1qR/p33 serves as a molecular bridge between the complement and contact activation systems and is an important catalyst in inflammation. Adv Exp Med Biol. 2006;586:95-105.
28. Yarovaya GA, Blokhina TB, Neshkova EA. Contact system. New concepts on activation mechanisms and bioregulatory functions. Biochem (Mosc). 2002;67:13-24.
29. Dobó J, Major B, Kékesi KA, et al. Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS One. 2011;6:e20036.
30. Genovese A, Rossi FW, Spadaro G, et al. Human cardiac mast cells in anaphylaxis. Chem Immunol Allergy. 2010;95:98-109.
31. Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol. 2008;153(suppl 1):7-11.
32. Marone G, de Crescenzo G, Adt M, et al. Immunological characterization and functional importance of human heart mast cells. Immunopharmacology. 1995;31:1-18.
33. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 2009;30:286-292.
34. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171:715-727.
35. Benson MD. Current concepts of immunology and diagnosis in amniotic fluid embolism. Clin Dev Immunol. 2012;2012:946576.
36. Kanayama N, Tamura N. Amniotic fluid embolism: pathophysiology and new strategies formanagement. J Obstet Gynaecol Res. 2014;40:1507-1517.
37. Szebeni J, Alving CR, Rosivall L, et al. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res. 2007;17: 107-117.
38. Hammerschmidt DE, Ogburn PL, Williams JE. Amniotic fluid activates complement. A role in amniotic fluid embolism syndrome? J Lab Clin Med. 1984;104:901-907.
39. Fineschi V, Riezzo I, Cantatore S, et al. Complement C3a expression and tryptase degranulation as promising histopathological tests for diagnosing fatal amniotic fluid embolism. Virchows Arch. 2009;454:283-290.
40. Tamura N, Nagai H, Maeda H, et al. Amniotic fluid embolism induces uterine anaphylaxis and atony following cervical laceration. Gynecol Obstet Invest. 2014;78:65-68.
41. Renné T, Schuh K, Müller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol. 2005;175:3377-3385.